Hormone therapy for prostate cancer may impair cognition

The Hormone deprivation therapy, also known as androgen depletion therapy, basically involves androgen depletion through chemical castration with drugs such as leuprolide and goserelin.

Prostate cancer patients who are prescribed these drugs often stay on them for the duration of their life, and the researchers have been documenting the potential adverse effects associated with their use.

New research from at Memorial Sloan-Kettering Cancer Center in New York City suggests that hormone deprivation therapy, which is commonly used to treat prostate cancer, may adversely affect cognition in patients.

The finding that hormone deprivation therapy may impair the ability to recall and concentrate in some patients results from a review of previous studies, appearing in the journal CANCER.